Abdelfattah, E.K.; Hosny, S.M.; Kassem, A.B.; Moustafa, H.A.M.; Tawfeik, A.M.; Abdelhafez, M.N.; El-Sheshtawy, W.; Alsfouk, B.A.; Saleh, A.; Salem, H.A.
Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) Regimen. Pharmaceuticals 2025, 18, 539.
https://doi.org/10.3390/ph18040539
AMA Style
Abdelfattah EK, Hosny SM, Kassem AB, Moustafa HAM, Tawfeik AM, Abdelhafez MN, El-Sheshtawy W, Alsfouk BA, Saleh A, Salem HA.
Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) Regimen. Pharmaceuticals. 2025; 18(4):539.
https://doi.org/10.3390/ph18040539
Chicago/Turabian Style
Abdelfattah, Esraa K., Sanaa M. Hosny, Amira B. Kassem, Hebatallah Ahmed Mohamed Moustafa, Amany M. Tawfeik, Marwa N. Abdelhafez, Wael El-Sheshtawy, Bshra A. Alsfouk, Asmaa Saleh, and Hoda A. Salem.
2025. "Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) Regimen" Pharmaceuticals 18, no. 4: 539.
https://doi.org/10.3390/ph18040539
APA Style
Abdelfattah, E. K., Hosny, S. M., Kassem, A. B., Moustafa, H. A. M., Tawfeik, A. M., Abdelhafez, M. N., El-Sheshtawy, W., Alsfouk, B. A., Saleh, A., & Salem, H. A.
(2025). Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) Regimen. Pharmaceuticals, 18(4), 539.
https://doi.org/10.3390/ph18040539
